BRAINSTORM CELL THERAPEUTICS (BCLI) Forecast, Price Target & Analyst Ratings

NASDAQ:BCLI • US10501E3009

Current stock price

1.17 USD
-0.03 (-2.5%)
At close:
0.67 USD
-0.5 (-42.74%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRAINSTORM CELL THERAPEUTICS (BCLI).

Forecast Snapshot

Consensus Price Target

Price Target
$15.47
+ 1,222.51% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 12, 2025
Period
Q2 / 2025
EPS Estimate
-$0.38
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.86%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$15.47
Upside
+ 1,222.51%
From current price of $1.17 to mean target of $15.47, Based on 7 analyst forecasts
Low
$6.06
Median
$17.34
High
$23.64

Price Target Revisions

1 Month
21.33%
3 Months
21.33%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for BCLI. The average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.
The average price target has been revised upward by 21.33% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BCLI Current Analyst RatingBCLI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

BCLI Historical Analyst RatingsBCLI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
82.86%
BCLI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BCLI.
In the previous month the buy percentage consensus was at a similar level.
BCLI was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2025-07-23Maxim GroupDowngrade Buy -> Hold
2024-07-11Maxim GroupUpgrade Hold -> Buy
2023-09-28Maxim GroupDowngrade Buy -> Hold
2023-03-31Maxim GroupMaintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 12, 2025
Period
Q2 / 2025
EPS Estimate
-$0.38
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
37.10%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A

Next Earnings Summary

BCLI is expected to report earnings on 8/12/2025. The consensus EPS estimate for the next earnings is -0.38 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2032

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
BCLI revenue by date.BCLI revenue by date.
N/AN/AN/AN/AN/A
149.71%		N/A
77.66%		N/A
-36.70%		N/A
48.86%
EBITDA
YoY % growth
BCLI ebitda by date.BCLI ebitda by date.
-8.45M-5M
40.83%		-4.91M
1.80%		-13.95M
-184.11%		-22.84M
-63.73%		-31.46M
-37.74%		-24.28M
22.82%		-24.53M
-1.03%		-21.174M
13.68%		-11.453M
45.91%		N/A
-33.59%		N/A
-53.33%		N/A
26.09%		N/A
494.12%		N/A
174.63%		N/A
66.85%		N/AN/A
EBIT
YoY % growth
BCLI ebit by date.BCLI ebit by date.
-8.54M-5.08M
40.52%		-5M
1.57%		-14.06M
-181.20%		-23M
-63.58%		-31.68M
-37.74%		-24.54M
22.54%		-24.82M
-1.14%		-21.439M
13.62%		-11.693M
45.46%		N/A
-53.06%		N/A
-18.78%		N/A
-16.10%		N/A
200.66%		N/A
-121.65%		N/A
1,000.57%		N/A
172.62%		N/A
62.35%
Operating Margin
BCLI operating margin by date.BCLI operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BCLI eps by date.BCLI eps by date.
-6.75-4.20
37.78%		-4.05
3.57%		N/A
-115.33%		-15.90
-82.32%		-16.20
-1.89%		-10.20
37.04%		-9.90
2.94%		N/A
-8.18%		-2.37
77.87%		N/A
33.08%		N/A
37.30%		N/A
15.90%		N/A
285.37%		N/A
9.21%		N/A
105.42%		N/A
-13.20%		N/A
59.12%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26
EPS
Q2Q % growth		-0.38
37.10%		-0.42
18.00%		-0.35
31.00%		-0.30
34.27%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-4.016M
-34.67%		-5.132M
-68.36%		-5.594M
-75.41%		-6.19M
-100.40%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BCLI Yearly Revenue VS EstimatesBCLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2028 2029 2030 2031 2032 100M 200M 300M
BCLI Yearly EPS VS EstimatesBCLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
18.10%
EPS Next 5 Year
22.11%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-9.08%
EBIT Next 5 Year
74.22%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BRAINSTORM CELL THERAPEUTICS / BCLI Forecast FAQ

What is the average price target for BRAINSTORM CELL THERAPEUTICS (BCLI) stock?

7 analysts have analysed BCLI and the average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.

Can you provide the upcoming earnings date for BRAINSTORM CELL THERAPEUTICS?

BRAINSTORM CELL THERAPEUTICS (BCLI) will report earnings on 2025-08-12.

What are the consensus estimates for BCLI stock next earnings?

The consensus EPS estimate for the next earnings of BRAINSTORM CELL THERAPEUTICS (BCLI) is -0.38 USD and the consensus revenue estimate is 0 USD.